Author’s response to reviews

Title: IMPACT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS CONTINUATION VERSUS DISCONTINUATION ON OUTCOME AFTER MAJOR SURGERY: PROTOCOL OF A MULTICENTER RANDOMIZED, CONTROLLED TRIAL (STOP-OR-NOT TRIAL)

Authors:

Matthieu Legrand (matthieu.m.legrand@gmail.com)
Emmanuel Futier (efutier@chu-clermontferrand.fr)
Marc Leone (marc.leone@ap-hm.fr)
Benjamin Deniau (benjdeniau@gmail.com)
Alexandre Mebazaa (alexandre.mebazaa@aphp.fr)
Benoit Plaud (benoit.plaud@aphp.fr)
Pierre Coriat (pierre.coriat@aphp.fr)
Patrick Rossignol (p.rossignol@chu-nancy.fr)
Eric Vicaut (eric.vicaut@aphp.fr)
Etienne Gayat (etienne.gayat@aphp.fr)

Version: 2 Date: 10 Jan 2019

Author’s response to reviews:

Dear Editor,

We would like to thank you for giving us the opportunity to submit a revised version. We also thank the reviewers for their careful assessment of the manuscript and their comments, which allowed us to improve the quality of the manuscript. We have replied point-by-point to the reviewers’ comments. Our replies are provided below. All modifications appear in red in the revised version of the manuscript.

As before, all authors have approved the revision and none of the contents have been published elsewhere.
We hope that this revised version of the manuscript will satisfy the editorial team and the reviewers. We remain at your entire disposal for any further indication.

Sincerely yours

Pr Legrand, on behalf of the authors

Reviewer #1: Dear author, thank you for revising your manuscript. All major issues have been edited. best regards

Reply: Thank you.

Reviewer #2: I had the chance to review the revised manuscript entitled IMPACT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS CONTINUATION VERSUS DISCONTINUATION ON OUTCOME AFTER MAJOR SURGERY: PROTOCOL OF A MULTICENTER RANDOMIZED, CONTROLLED TRIAL (STOPOR-NOT TRIAL).

The authors have adequately responded to the questions/issues raised during review.

Here are some minor comments/corrections:

Page 5: "The list is inserted into the Clean Web-based software and then forwarded to the sponsor's quality insurance team for validation. "

I Think Clean Web is a company/commercial product so maybe details should be added in parenthesis.
Page 10: "(i.e. due to the higher nombre of medications containing a ACEi or ARB)"

Change nombre for number

Reply : Thank you for reviewing the manuscript and your constructive comments. We have corrected the manuscript accordingly.

Reviewer #3: Dear Authors,

many thanks to consider our revisions. I'm willing to consider this manuscript suitable for publication but you need to provide a flow diagram as stated in the consort guideline.

Reply : Thank you for reviewing the manuscript. We have added a CONSORT flow diagram as a new Figure 3 as well as a schematic representation of the trial for participants (supplement